These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis. Azie N; Angulo D; Dehn B; Sobel JD Expert Opin Investig Drugs; 2020 Sep; 29(9):893-900. PubMed ID: 32746636 [TBL] [Abstract][Full Text] [Related]
13. In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis. Boikov DA; Locke JB; James KD; Bartizal K; Sobel JD J Antimicrob Chemother; 2017 May; 72(5):1355-1358. PubMed ID: 28158577 [TBL] [Abstract][Full Text] [Related]
14. The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation. Larkin E; Hager C; Chandra J; Mukherjee PK; Retuerto M; Salem I; Long L; Isham N; Kovanda L; Borroto-Esoda K; Wring S; Angulo D; Ghannoum M Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223375 [No Abstract] [Full Text] [Related]
15. Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Gamal A; Chu S; McCormick TS; Borroto-Esoda K; Angulo D; Ghannoum MA Front Cell Infect Microbiol; 2021; 11():642358. PubMed ID: 33791244 [TBL] [Abstract][Full Text] [Related]
17. SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies. Scorneaux B; Angulo D; Borroto-Esoda K; Ghannoum M; Peel M; Wring S Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069658 [TBL] [Abstract][Full Text] [Related]
18. Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use. Danby CS; Boikov D; Rautemaa-Richardson R; Sobel JD Antimicrob Agents Chemother; 2012 Mar; 56(3):1403-6. PubMed ID: 22232293 [TBL] [Abstract][Full Text] [Related]